José Luis Piñana, Inmaculada Heras, Tommaso Francesco Aiello, Irene García-Cadenas, Lourdes Vazquez, Javier Lopez-Jimenez, Pedro Chorão, Cristina Aroca, Carolina García-Vidal, Ignacio Arroyo, Eva Soler-Espejo, Lucia López-Corral, Alejandro Avendaño-Pita, Anna Arrufat, Valentín Garcia-Gutierrez, Elena Arellano, Lorena Hernández-Medina, Clara González-Santillana, Julia Morell, José Ángel Hernández-Rivas, Paula Rodriguez-Galvez, Mireia Mico-Cerdá, Manuel Guerreiro, Diana Campos, David Navarro, Ángel Cedillo, Rodrigo Martino, Carlos Solano
BACKGROUND: Scarce data exist that analyze the outcomes of hematological patients with SARS-CoV-2 infection during the Omicron variant period who received treatment with remdesivir or nirmatrelvir/ritonavir. METHODS: This study aims to address this issue by using a retrospective observational registry, created by the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group, spanning from 27 December 2021 to 30 April 2023. RESULTS: This study included 466 patients, 243 (52%) who were treated with remdesivir and 223 (48%) with nirmatrelvir/ritonavir...
October 8, 2023: Viruses